9Y4 logo

Ryvu Therapeutics DB:9Y4 Stock Report

Last Price

€6.43

Market Cap

€142.6m

7D

-7.3%

1Y

-50.8%

Updated

02 Feb, 2025

Data

Company Financials +

Ryvu Therapeutics S.A.

DB:9Y4 Stock Report

Market Cap: €142.6m

9Y4 Stock Overview

A biotechnology company, engages in developing of small molecule therapies for treatment in oncology in Poland, rest of the European Union, and internationally. More details

9Y4 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Revenue is forecast to grow 19.3% per year

Risk Analysis

Earnings are forecast to decline by an average of 10.1% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the German market


My Notes

Capture your thoughts, links and company narrative

Ryvu Therapeutics S.A. Competitors

Evotec

XTRA:EVT

€1.5b

Gerresheimer

XTRA:GXI

€2.3b

SCHOTT Pharma KGaA

XTRA:1SXP

€3.6b

Vitruvia Medical

MUN:991

€3.2m

Price History & Performance

Summary of share price highs, lows and changes for Ryvu Therapeutics
Historical stock prices
Current Share Pricezł6.43
52 Week Highzł13.62
52 Week Lowzł6.43
Beta0.65
1 Month Change-31.16%
3 Month Change-35.83%
1 Year Change-50.77%
3 Year Change-45.32%
5 Year Changen/a
Change since IPO-40.46%

Recent News & Updates

Recent updates

Shareholder Returns

9Y4DE Life SciencesDE Market
7D-7.3%3.4%1.9%
1Y-50.8%3.1%15.1%

Return vs Industry: 9Y4 underperformed the German Life Sciences industry which returned 3.1% over the past year.

Return vs Market: 9Y4 underperformed the German Market which returned 15.1% over the past year.

Price Volatility

Is 9Y4's price volatile compared to industry and market?
9Y4 volatility
9Y4 Average Weekly Movement10.2%
Life Sciences Industry Average Movement7.6%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 9Y4's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 9Y4's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2007270Pawel Przewiezlikowskiryvu.com

Ryvu Therapeutics S.A., a biotechnology company, engages in developing of small molecule therapies for treatment in oncology in Poland, rest of the European Union, and internationally. Its lead candidate, RVU120, is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat hematological malignancies, solid tumors, acute myeloid leukemia, myelodysplastic syndrome, and myelofibrosis. The company also develops SEL24/MEN1703, a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial for the treatment of diffuse large b-cell lymphoma and acute myeloid leukemia.

Ryvu Therapeutics S.A. Fundamentals Summary

How do Ryvu Therapeutics's earnings and revenue compare to its market cap?
9Y4 fundamental statistics
Market cap€142.60m
Earnings (TTM)-€24.70m
Revenue (TTM)€21.63m

6.6x

P/S Ratio

-5.8x

P/E Ratio

Is 9Y4 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
9Y4 income statement (TTM)
Revenuezł91.18m
Cost of Revenuezł18.68m
Gross Profitzł72.50m
Other Expenseszł176.63m
Earnings-zł104.14m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-4.50
Gross Margin79.51%
Net Profit Margin-114.21%
Debt/Equity Ratio45.3%

How did 9Y4 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 22:47
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ryvu Therapeutics S.A. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamil KliszczBiuro maklerskie mBanku
Beata Szparaga-WasniewskaBiuro maklerskie mBanku
Jonas PeciulisEdison Investment Research